Areg Hovhannisyan

926 total citations
12 papers, 697 citations indexed

About

Areg Hovhannisyan is a scholar working on Molecular Biology, Pharmacology and Complementary and alternative medicine. According to data from OpenAlex, Areg Hovhannisyan has authored 12 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Pharmacology and 5 papers in Complementary and alternative medicine. Recurrent topics in Areg Hovhannisyan's work include Andrographolide Research and Applications (5 papers), Medicinal Plants and Bioactive Compounds (5 papers) and Pharmacological Effects of Natural Compounds (4 papers). Areg Hovhannisyan is often cited by papers focused on Andrographolide Research and Applications (5 papers), Medicinal Plants and Bioactive Compounds (5 papers) and Pharmacological Effects of Natural Compounds (4 papers). Areg Hovhannisyan collaborates with scholars based in Armenia, Sweden and Georgia. Areg Hovhannisyan's co-authors include Alexander Panossian, G. Wikman, Heidemarie Abrahamian, E. Gabrielyan, E. Gabrielian, Hildebert Wagner and Jürgen Arnhold and has published in prestigious journals such as Phytotherapy Research, Phytomedicine and BMC Complementary and Alternative Medicine.

In The Last Decade

Areg Hovhannisyan

12 papers receiving 662 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Areg Hovhannisyan Armenia 11 335 271 161 153 149 12 697
Carla F.S. Guazelli Brazil 10 196 0.6× 59 0.2× 144 0.9× 80 0.5× 31 0.2× 13 636
Yuan Yue China 6 192 0.6× 45 0.2× 60 0.4× 79 0.5× 262 1.8× 9 568
Pei‐Yi Chu Taiwan 17 159 0.5× 70 0.3× 109 0.7× 56 0.4× 49 0.3× 36 707
Mingyue Ao China 4 176 0.5× 50 0.2× 88 0.5× 65 0.4× 238 1.6× 5 548
Xiao‐Jie Gong China 16 418 1.2× 64 0.2× 161 1.0× 60 0.4× 28 0.2× 43 784
Chandradhara Divya India 9 143 0.4× 38 0.1× 70 0.4× 95 0.6× 208 1.4× 15 468
Arghavan Memarzia Iran 15 181 0.5× 66 0.2× 101 0.6× 34 0.2× 102 0.7× 27 530
Pidaran Murugan India 13 251 0.7× 59 0.2× 80 0.5× 117 0.8× 478 3.2× 21 822
Guru R. Valicherla India 19 220 0.7× 76 0.3× 76 0.5× 55 0.4× 35 0.2× 32 662
Benny Antony India 8 131 0.4× 73 0.3× 52 0.3× 85 0.6× 182 1.2× 17 375

Countries citing papers authored by Areg Hovhannisyan

Since Specialization
Citations

This map shows the geographic impact of Areg Hovhannisyan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Areg Hovhannisyan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Areg Hovhannisyan more than expected).

Fields of papers citing papers by Areg Hovhannisyan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Areg Hovhannisyan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Areg Hovhannisyan. The network helps show where Areg Hovhannisyan may publish in the future.

Co-authorship network of co-authors of Areg Hovhannisyan

This figure shows the co-authorship network connecting the top 25 collaborators of Areg Hovhannisyan. A scholar is included among the top collaborators of Areg Hovhannisyan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Areg Hovhannisyan. Areg Hovhannisyan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Hovhannisyan, Areg, et al.. (2023). Efficacy of Kan Jang® in Patients with Mild COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial. Pharmaceuticals. 16(9). 1196–1196. 2 indexed citations
2.
Hovhannisyan, Areg, et al.. (2022). Efficacy of Adaptogens in Patients with Long COVID-19: A Randomized, Quadruple-Blind, Placebo-Controlled Trial. Pharmaceuticals. 15(3). 345–345. 17 indexed citations
3.
Hovhannisyan, Areg, et al.. (2022). Efficacy of Kan Jang® in Patients with Mild COVID-19: Interim Analysis of a Randomized, Quadruple-Blind, Placebo-Controlled Trial. Pharmaceuticals. 15(8). 1013–1013. 10 indexed citations
4.
5.
6.
Hovhannisyan, Areg, et al.. (2018). Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study. BMC Complementary and Alternative Medicine. 18(1). 7–7. 159 indexed citations
7.
8.
Hovhannisyan, Areg, et al.. (2015). Efficacy of Adaptogenic Supplements on Adapting to Stress: A Randomized, Controlled Trial. 4(4). 13 indexed citations
9.
Panossian, Alexander, et al.. (2008). Pharmacokinetic and pharmacodynamic study of interaction ofRhodiola roseaSHR‐5 extract with warfarin and theophylline in rats. Phytotherapy Research. 23(3). 351–357. 30 indexed citations
10.
Panossian, Alexander, et al.. (2007). Comparative study of Rhodiola preparations on behavioral despair of rats. Phytomedicine. 15(1-2). 84–91. 80 indexed citations
11.
Hovhannisyan, Areg, et al.. (2005). The effect of Kan Jang extract on the pharmacokinetics and pharmacodynamics of warfarin in rats. Phytomedicine. 13(5). 318–323. 15 indexed citations
12.
Panossian, Alexander, Areg Hovhannisyan, Heidemarie Abrahamian, et al.. (2000). Pharmacokinetic and oral bioavailability of andrographolide from Andrographis paniculata fixed combination Kan Jang in rats and human. Phytomedicine. 7(5). 351–364. 185 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carla F.S. Guazelli Breakdown of academic impact, for papers by Yuan Yue Breakdown of academic impact, for papers by Pei‐Yi Chu Breakdown of academic impact, for papers by Mingyue Ao Breakdown of academic impact, for papers by Xiao‐Jie Gong Breakdown of academic impact, for papers by Chandradhara Divya Breakdown of academic impact, for papers by Arghavan Memarzia Breakdown of academic impact, for papers by Pidaran Murugan Breakdown of academic impact, for papers by Guru R. Valicherla Breakdown of academic impact, for papers by Benny Antony
Rankless by CCL
2026